Furthermore, HLA DR+ CD4+ T cells were significantly enriched in the peripheral blood of patients responding to immunotherapy in a pan-cancer study, demonstrating their potential for predicting immunotherapy responses [22]. This evidence concerns the gene CD4 and cancer.